FASLG and antiphospholipid syndrome: The adjusted Global Antiphospholipid Syndrome Score (aGAPSS), which incorporates independent CVD risk factors along with the serum aPL profile, has been proposed as a tool in predicting CVD risk in patients with SLE [75].